

A Study to Evaluate BMS-986470 in Healthy Volunteers and Participants With Sickle Cell Disease

NCT06481306

Status	RECRUITING
Phase	Phase 1, Phase 2
Sponsor	Bristol-Myers Squibb
Enrollment	184 participants

Key Eligibility Criteria

Inclusion (13)

- Cohort A.
- i) Healthy male and female (who are not of childbearing potential) participants, as determined by the investigator based on medical history and other determinations. Females not of childbearing potential must have been amenorrhoeic for at least 12 months without an alternative medical cause and have follicle-stimulating hormone (FSH) levels of at least 40 IU/L or have undergone a hysterectomy, bilateral oophorectomy, or bilateral salpingectomy.
- ii) Body mass index (BMI) of 18.0 to 32.0 kg/m², inclusive. BMI = weight (kg)/ (height [m])² as measured at screening.
- iii) No evidence of organ dysfunction or any clinically significant deviation from normal in physical examination, vital signs, ECG, or clinical laboratory assessments beyond what is consistent with the target population.

- Cohort B.

... and 8 more (see full listing online)

Exclusion (11)

- Cohort A.
- i) Any significant medical condition or any condition that confounds the ability to interpret data from the study.
- ii) Participant has any condition, including the presence of laboratory abnormalities, that places the participant at unacceptable risk if the participant was to participate in the study.
- iii) Any major surgery or planned surgery (except GI surgery) within 12 weeks of the first study intervention administration.

- Cohort B.

... and 6 more (see full listing online)

Locations (19 total)

University of Alabama at Birmingham, Birmingham, Alabama, United States
University of California San Diego - La Jolla, La Jolla, California, United States
UCSF Benioff Children's Hospital Oakland, Oakland, California, United States
... and 16 more locations